Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

R 289

Next Previous
Drug Profile

R 289

Alternative Names: R-289; R835 prodrug - Rigel Pharmaceuticals

Latest Information Update: 14 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rigel Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Myelodysplastic syndromes

Most Recent Events

  • 09 Jan 2025 R 289 receives Orphan Drug status for Myelodysplastic syndromes in USA
  • 31 Dec 2024 Rigel Pharmaceuticals has patent protection for R 289 in USA
  • 31 Dec 2024 Rigel Pharmaceuticals has patents pending for R 289 in multiple countries Worldwide

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top